Group 1 - On February 2, 2023, Hotgen Biotech experienced a decline of 5.36% with a trading volume of 211 million yuan. The financing data indicated a net buying of 1.17 million yuan for the day, with a total financing and margin balance of 156 million yuan [1] - The financing balance of Hotgen Biotech was reported at 154 million yuan, accounting for 1.21% of the circulating market value, which is below the 50th percentile level over the past year, indicating a low position [1] - In terms of securities lending, Hotgen Biotech had a securities lending balance of 2.27 million yuan, which is above the 90th percentile level over the past year, indicating a high position [1] Group 2 - As of September 30, 2023, Hotgen Biotech had 7,833 shareholders, an increase of 12.9% from the previous period. The average circulating shares per person decreased by 11.43% to 11,835 shares [2] - For the period from January to September 2023, Hotgen Biotech reported a revenue of 310 million yuan, a year-on-year decrease of 19.8%. The net profit attributable to the parent company was -109 million yuan, a significant decrease of 168.12% [2] - Since its A-share listing, Hotgen Biotech has distributed a total of 440 million yuan in dividends, with 17.34 million yuan distributed over the past three years [3]

1月27日，热景生物涨5.05%，截至发稿，报154.89元/股，成交2.70亿元，换手率1.92%，总市值143.60 亿元。 资料显示，北京热景生物技术股份有限公司位于北京市大兴区中关村科技园区大兴生物医药产业基地庆 丰西路55号院7号楼1-5层，成立日期2005年6月23日，上市日期2019年9月30日，公司主营业务涉及研 发、生产和销售体外诊断试剂及仪器。主营业务收入构成为：检测试剂70.87%，检测仪器19.79%，其 他8.17%，生物原料1.17%。 截至发稿，农冰立累计任职时间7年222天，现任基金资产总规模126.84亿元，任职期间最佳基金回报 174.01%， 任职期间最差基金回报-1.57%。 声明：市场有风险，投资需谨慎。 本文基于第三方数据库自动发布，任何在本文出现的信息（包括但 不限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成个人投资建 议。受限于第三方数据库质量等问题，我们无法对数据的真实性及完整性进行分辨或核验，因此本文内 容可能出现不准确、不完整、误导性的内容或信息，具体以公司公告为准。如有疑问，请联系 biz@staff.sina.com.c ...

Group 1 - The core viewpoint of the news is that Antu Biology's stock has increased by 5.98%, reaching a price of 39.54 yuan per share, with a trading volume of 260 million yuan and a turnover rate of 1.20%, resulting in a total market capitalization of 22.594 billion yuan [1] - Antu Biology, established on September 15, 1999, and listed on September 1, 2016, specializes in the research, production, and sales of in vitro diagnostic reagents and instruments, with its main business revenue composition being 86.63% from reagents, 10.99% from instruments, 1.40% from other sources, and 0.98% from maintenance income [1] - Changjiang Asset Management holds a significant position in Antu Biology through its fund, Changjiang Xuri Mixed A (021015), which held 71,000 shares in the fourth quarter, accounting for 2.47% of the fund's net value, ranking as the tenth largest holding [1] Group 2 - The fund manager of Changjiang Xuri Mixed A (021015) is Shi Zhan, who has been in the position for 4 years and 30 days, with the fund's total asset size being 802 million yuan [2] - During Shi Zhan's tenure, the best fund return was 53.53%, while the worst return was 48.76% [2]

Core Viewpoint - The company, 热景生物, is forecasting a significant decline in its 2025 financial performance, with expected revenues between 400 million to 420 million yuan, representing a year-on-year decrease of 17.79% to 21.71%, and a net loss projected between 210 million to 230 million yuan, which is an increase from the previous year's loss of 191 million yuan [2] Financial Performance - The company's revenue peaked at 3.556 billion yuan in 2022, with a profit of 944 million yuan, but has since faced two consecutive years of losses [3] - In 2024, the company reported revenues of 511 million yuan and a net loss of 191 million yuan, with a non-recurring net loss of 231 million yuan [3] - By the third quarter of 2025, revenues were 310 million yuan, a year-on-year decline of 19.8%, with a net loss of 109 million yuan [3] Industry Challenges - The in vitro diagnostic industry is facing significant challenges due to policy changes, particularly centralized procurement, which has impacted product pricing and increased competition [3][4] - The company's main business, in vitro diagnostic reagents and instruments, accounts for 99% of its revenue, and the pricing pressure has led to a decline in both single-machine revenue and output rates [3] Revenue Dynamics - In 2024, excluding non-conventional testing, the company's revenue grew by 23.10%, but reagent business revenue fell by 18.55%, with growth primarily driven by instrument sales, which saw a 262.79% increase in volume and a 289.79% increase in revenue [3] - The gross margin for instruments improved from -11.20% to 6.41% due to adjustments in sales strategy [3] Strategic Adjustments - The company shifted its sales strategy in the second half of 2023 to a model that combines sales and deployment, responding to increased demand from hospitals [4] - However, this strategy has led to a lag in reagent sales growth, which increased by only 8.24% compared to a 13.21% growth in instrument sales [4] Investment in Innovation - In response to stagnant growth in its core business, the company has invested in innovative pharmaceuticals, including stakes in 舜景医药, 尧景基因, and 智源生物, but these investments have not yet generated revenue and have resulted in significant losses [5] - The company reported an investment loss of 47.63 million yuan in 2024 and has increased its stake in 舜景医药, which is now a subsidiary [5] - 舜景医药 is developing SGC001, a novel treatment for acute myocardial infarction, which has received clinical trial approval but is still in the early stages of development [5]

Core Viewpoint - Mingde Bio plans to acquire 51% of Hunan Lanyi Medical Instrument Co., Ltd. for 35.71 million yuan, aiming to expand its medical service ecosystem and enhance its capabilities in chronic disease management [1][2]. Group 1: Acquisition Details - The acquisition will occur in two phases, with the first phase involving the purchase of 51% equity for 35.71 million yuan, making Hunan Lanyi a subsidiary of Mingde Bio [1][3]. - The transaction structure includes a capital increase of 20 million yuan for 28.57% equity and a purchase of 15.71 million yuan for 22.43% equity from the existing shareholders [3]. - If Hunan Lanyi meets performance conditions from 2026 to 2028, Mingde Bio will acquire the remaining 49% equity [1][3]. Group 2: Hunan Lanyi Overview - Hunan Lanyi, established in September 2020, focuses on the R&D and production of IVD instruments and reagents, particularly in glycated hemoglobin testing [2]. - The company reported revenues of 30.66 million yuan and a net loss of 23.98 million yuan for the first nine months of 2025, indicating growth potential due to increasing demand in the healthcare sector [2]. Group 3: Strategic Implications - The acquisition aims to create a comprehensive medical service platform that integrates acute and chronic disease management, enhancing service capabilities for healthcare institutions [4]. - Mingde Bio is also pursuing additional acquisitions, including a planned purchase of 100% of Wuhan Bikaier Rescue Supplies Co., Ltd. to further develop its acute care business segment [4].

从基金十大重仓股角度 截至发稿，华龙累计任职时间3年148天，现任基金资产总规模359.57亿元，任职期间最佳基金回报 139.26%， 任职期间最差基金回报-15.08%。 风险提示：市场有风险，投资需谨慎。本文为AI大模型自动发布，任何在本文出现的信息（包括但不 限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成个人投资建 议。 数据显示，华夏基金旗下1只基金重仓热景生物。华夏上证科创板200ETF（588820）三季度增持2.8万 股，持有股数2.96万股，占基金净值比例为1.06%，位居第十大重仓股。根据测算，今日浮亏损失约 28.63万元。 华夏上证科创板200ETF（588820）成立日期2024年12月23日，最新规模4.76亿。今年以来收益 14.98%，同类排名260/5525；近一年收益81.01%，同类排名241/4208；成立以来收益85.97%。 华夏上证科创板200ETF（588820）基金经理为华龙。 1月15日，热景生物跌5.12%，截至发稿，报179.31元/股，成交1.66亿元，换手率0.98%，总市值166.23 亿元。 资料显示，北京热景生物 ...

Core Viewpoint - The stock of Hotgen Biotech has shown a mixed performance in recent trading, with a year-to-date increase of 18.12% but a slight decline over the past five days, indicating potential volatility in investor sentiment [1]. Financial Performance - For the period from January to September 2025, Hotgen Biotech reported a revenue of 310 million yuan, representing a year-on-year decrease of 19.80% [2]. - The company experienced a net loss attributable to shareholders of 109 million yuan, which is a significant decline of 168.12% compared to the previous year [2]. Shareholder and Market Activity - As of September 30, 2025, the number of shareholders increased by 12.90% to 7,833, while the average number of circulating shares per person decreased by 11.43% to 11,835 shares [2]. - The stock price reached 191.36 yuan per share with a market capitalization of 17.741 billion yuan, and the trading volume was 168 million yuan, indicating active market participation [1]. Dividends and Institutional Holdings - Since its A-share listing, Hotgen Biotech has distributed a total of 440 million yuan in dividends, with 17.344 million yuan paid out in the last three years [3]. - Among the top ten circulating shareholders, notable changes include a decrease in holdings by Huatai-PineBridge Innovation Medicine Mixed Fund and an increase by ICBC Frontier Medical Stock A [3].

Core Viewpoint - Antu Biology's stock performance shows a slight increase, with a trading volume of 1.11 billion yuan and a net financing buy of 640,600 yuan on January 6, indicating low financing levels compared to historical data [1] Financing Summary - On January 6, Antu Biology had a financing buy of 13.26 million yuan and a financing repayment of 12.62 million yuan, resulting in a net financing buy of 640,600 yuan [1] - The total financing and securities lending balance for Antu Biology reached 463 million yuan, with the financing balance at 459 million yuan, accounting for 2.21% of the circulating market value, which is below the 10th percentile of the past year [1] - The securities lending data shows a repayment of 700 shares and a sale of 600 shares, with a total sale amount of 21,800 yuan, and a securities lending balance of 3.99 million yuan, also below the 50th percentile of the past year [1] Company Performance Summary - As of September 30, Antu Biology had 34,000 shareholders, a decrease of 0.58% from the previous period, with an average of 16,816 circulating shares per shareholder, an increase of 0.58% [2] - For the period from January to September 2025, Antu Biology reported a revenue of 3.13 billion yuan, a year-on-year decrease of 7.48%, and a net profit attributable to shareholders of 860 million yuan, down 10.11% year-on-year [2] - Since its A-share listing, Antu Biology has distributed a total of 4.05 billion yuan in dividends, with 1.79 billion yuan distributed over the past three years [2] Shareholder Structure Summary - As of September 30, 2025, the top ten circulating shareholders of Antu Biology include Zhonggeng Value Pioneer Stock, holding 7.84 million shares, a decrease of 1.42 million shares from the previous period [2] - Hong Kong Central Clearing Limited is the fourth largest shareholder with 7.15 million shares, an increase of 421,430 shares [2] - Other notable changes include a decrease in holdings by Huabao Zhongzheng Medical ETF and an increase in holdings by Dachen Rui Xiang Mixed A and Dachen Competitive Advantage Mixed A [2]

Core Viewpoint - The stock of Hotgen Biotech has shown a slight increase of 2.07% as of January 5, 2025, with a current price of 165.35 CNY per share, despite a net outflow of funds from major investors [1] Group 1: Stock Performance - As of January 5, 2025, Hotgen Biotech's stock price increased by 2.07% year-to-date, but has decreased by 0.99% over the last five trading days and by 7.89% over the last twenty days [1] - The total market capitalization of Hotgen Biotech is 15.329 billion CNY [1] Group 2: Financial Performance - For the period from January to September 2025, Hotgen Biotech reported a revenue of 310 million CNY, representing a year-on-year decrease of 19.80% [2] - The company recorded a net profit attributable to shareholders of -109 million CNY, a significant decline of 168.12% compared to the previous year [2] Group 3: Shareholder Information - As of September 30, 2025, the number of shareholders for Hotgen Biotech increased by 12.90% to 7,833 [2] - The average number of circulating shares per shareholder decreased by 11.43% to 11,835 shares [2] Group 4: Dividend and Institutional Holdings - Since its A-share listing, Hotgen Biotech has distributed a total of 440 million CNY in dividends, with 17.344 million CNY distributed over the last three years [3] - Among the top ten circulating shareholders, notable changes include a decrease of 125,300 shares held by Huatai-PineBridge Innovation Medical Mixed Fund and an increase of 500,000 shares held by ICBC Frontier Medical Stock Fund [3]

责任编辑：小浪快报 资料显示，郑州安图生物工程股份有限公司位于河南省郑州经济技术开发区经开第十五大街199号，成 立日期1999年9月15日，上市日期2016年9月1日，公司主营业务涉及体外诊断试剂及仪器的研发、生产 和销售。主营业务收入构成为：试剂86.63%，仪器10.99%，其他1.40%，维保收入0.98%。 截至9月30日，安图生物股东户数3.40万，较上期减少0.58%；人均流通股16816股，较上期增加0.58%。 2025年1月-9月，安图生物实现营业收入31.27亿元，同比减少7.48%；归母净利润8.60亿元，同比减少 10.11%。 分红方面，安图生物A股上市后累计派现40.46亿元。近三年，累计派现17.94亿元。 机构持仓方面，截止2025年9月30日，安图生物十大流通股东中，中庚价值先锋股票（012930）位居第 三大流通股东，持股783.61万股，相比上期减少141.73万股。香港中央结算有限公司位居第四大流通股 东，持股714.85万股，相比上期增加421.43万股。华宝中证医疗ETF（512170）位居第五大流通股东， 持股483.37万股，相比上期减少90.91万股。大成睿 ...